{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:45:01Z","timestamp":1786985101115,"version":"build-2736575974"},"reference-count":58,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019175","name":"Scleroderma Society of Ontario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019175","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102104","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:43:06Z","timestamp":1759300986000},"page":"102104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel therapies in SSc"],"prefix":"10.1016","volume":"39","author":[{"given":"Janet","family":"Pope","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.berh.2025.102104_bib1","first-page":"556","article-title":"Pathogenesis of systemic sclerosis","volume":"11","author":"Allanore","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.berh.2025.102104_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41584-023-00909-5","article-title":"State-of-the-art evidence in the treatment of systemic sclerosis","volume":"19","author":"Pope","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2025.102104_bib3","series-title":"Textbook of autoimmune diseases","first-page":"387","article-title":"Systemic sclerosis: disease spectrum and classification","author":"Calderon-Martin","year":"2022"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib4","first-page":"378","article-title":"Predictive factors of disease progression in very early systemic sclerosis","volume":"62","author":"Avouac","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"13","key":"10.1016\/j.berh.2025.102104_bib47","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.berh.2025.102104_bib48","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.berh.2025.102104_bib55","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","article-title":"Treatment algorithms for systemic sclerosis according to experts","volume":"70","author":"Fern\u00e1ndez-Codina","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib5","first-page":"218","article-title":"Very early diagnosis of systemic sclerosis: recommendations from EULAR Scleroderma Trials and Research group","volume":"38","author":"Valentini","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2025.102104_bib6","article-title":"Biomarkers and fibrosis in systemic sclerosis","volume":"119","author":"Elhai","year":"2021","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib7","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2025.102104_bib8","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.berh.2025.102104_bib9","article-title":"EULAR recommendations for the treatment of systemic sclerosis: 2023 update","author":"Del Galdo","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib10","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.berh.2013.03.001","article-title":"Capillaroscopy in systemic sclerosis","volume":"27","author":"Cutolo","year":"2013","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib11","first-page":"28","article-title":"Capillaroscopy utility in systemic sclerosis","volume":"5","author":"Ingegnoli","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"12","key":"10.1016\/j.berh.2025.102104_bib12","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1136\/annrheumdis-2013-203716","article-title":"Preliminary analysis of the very early diagnosis of systemic sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis","volume":"73","author":"Minier","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2025.102104_bib13","first-page":"1351","article-title":"Systemic sclerosis classification criteria and very early disease","volume":"66","author":"Avouac","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.berh.2025.102104_bib14","article-title":"Biomarkers in systemic sclerosis","volume":"19","author":"Dolcino","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.berh.2025.102104_bib15","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/art.24681","article-title":"Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials","volume":"60","author":"Amjadi","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2025.102104_bib16","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/rheumatology\/kez529","article-title":"Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis","volume":"59","author":"Nevskaya","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib17","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/rheumatology\/kez299","article-title":"Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity","volume":"59","author":"Zheng","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/art.39501","article-title":"The American college of Rheumatology provisional composite response index for clinical trials in early diffuse cutaneous systemic sclerosis","volume":"68","author":"Khanna","year":"2016","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"10038","key":"10.1016\/j.berh.2025.102104_bib19","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.berh.2025.102104_bib20","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/annrheumdis-2020-219100","article-title":"New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis","volume":"80","author":"Khanna","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2025.102104_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-044765","article-title":"Domains and outcome measures for the assessment of limited cutaneous systemic sclerosis: a scoping review protocol","volume":"11","author":"Lescoat","year":"2021","journal-title":"BMJ Open"},{"issue":"25","key":"10.1016\/j.berh.2025.102104_bib22","first-page":"2499","article-title":"Mycophenolate vs cyclophosphamide in scleroderma lung disease (SLS II)","volume":"375","author":"Tashkin","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase II investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Tocilizumab in early systemic sclerosis: results from the focuSSced trial","volume":"72","author":"Khanna","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102104_bib25","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Rituximab in the DESIRES trial for systemic sclerosis","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.berh.2025.102104_bib26","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"Methotrexate in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2025.102104_bib27","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/rheumatology\/keae235","article-title":"Brentuximab vedotin for skin involvement in refractory diffuse cutaneous systemic sclerosis, an open-label trial","volume":"64","author":"Fern\u00e1ndez-Codina","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2025.102104_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s42358-021-00170-y","article-title":"Is rituximab effective for systemic sclerosis? A systematic review and meta-analysis","volume":"61","author":"de Figueiredo Caldas","year":"2021","journal-title":"Adv Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib29","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2025.102104_bib30","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.berh.2025.102104_bib32","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/BOR.0000000000000660","article-title":"Detection and classification of systemic sclerosis-related interstitial lung disease: a review","volume":"31","author":"DeMizio","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2025.102104_bib33","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib34","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations. An official American Thoracic Society clinical practice guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.berh.2025.102104_bib35","first-page":"706","article-title":"Rituximab and tocilizumab in systemic sclerosis\u2013associated interstitial lung disease","volume":"205","author":"Khanna","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"suppl 9","key":"10.1016\/j.berh.2025.102104_bib36","article-title":"Combination therapy of mycophenolate mofetil and pirfenidone vs. Mycophenolate alone: results from the scleroderma lung study III [abstract]","volume":"74","author":"Khanna","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/annrheumdis-2021-221605","article-title":"Advances in CAR-T trials for autoimmune disease","volume":"82","author":"Distler","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2025.102104_bib38","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"26","key":"10.1016\/j.berh.2025.102104_bib52","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib in systemic sclerosis\u2013associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2025.102104_bib39","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"Cyclophosphamide in early systemic sclerosis\u2013related interstitial lung disease","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2025.102104_bib40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/rheumatology\/kez407","article-title":"Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis","volume":"59","author":"Hoa","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3390\/jcm10020292","article-title":"A 3-year observational study of patients with progressive systemic sclerosis treated with an intensified B lymphocyte depletion protocol: clinical and immunological response","volume":"10","author":"Rossi","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.berh.2025.102104_bib42","series-title":"Efficacy and safety of nerandomilast in patients with autoimmune disease\u2013related progressive pulmonary fibrosis: subgroup analysis of the FIBRONEER-ILD trial. LB0003","author":"Hoffmann-Vold","year":"2025"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib58","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.berh.2025.102104_bib53","doi-asserted-by":"crossref","DOI":"10.1177\/00368504251333912","article-title":"Rituximab in systemic sclerosis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"108","author":"Jang","year":"2025","journal-title":"Sci Prog"},{"issue":"6","key":"10.1016\/j.berh.2025.102104_bib54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.berh.2025.102104_bib57","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2022-001580","article-title":"Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)","volume":"10","author":"Maher","year":"2023","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"10.1016\/j.berh.2025.102104_bib56","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3899\/jrheum.161040","article-title":"Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"45","author":"Hsu","year":"2018","journal-title":"J Rheumatol"},{"issue":"38","key":"10.1016\/j.berh.2025.102104_bib43","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Gali\u00e8","year":"2022","journal-title":"Eur Heart J"},{"issue":"25","key":"10.1016\/j.berh.2025.102104_bib44","first-page":"1860","article-title":"Epoprostenol in severe pulmonary arterial hypertension","volume":"342","author":"Badesch","year":"2000","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2025.102104_bib45","first-page":"866","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"389","author":"Simonneau","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.berh.2025.102104_bib46","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of Sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2025.102104_bib49","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2025.102104_bib50","first-page":"e187","article-title":"CD19 CAR-T cell therapy for autoimmune disease","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.berh.2025.102104_bib51","article-title":"T cell engagers in autoimmune diseases: early evidence in systemic sclerosis","volume":"193","author":"Subklewe","year":"2024","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.berh.2025.102104_bib31","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.3899\/jrheum.201049","article-title":"Systemic sclerosis and associated interstitial lung disease in Ontario, Canada: an examination of prevalence and survival over 10 years","volume":"48","author":"Pope","year":"2021","journal-title":"J Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:13:11Z","timestamp":1765386791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694225000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521694225000725"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102104","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies in SSc","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102104","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102104"}}